Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com

Articles

FDA Rejects NDA for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma

February 14th 2023

The FDA has issued a refusal to file letter for a new drug application seeking the approval of HyBryte, Soligenix’s synthetic hypericin, for use in patients with early-stage cutaneous T-cell lymphoma.

NCCN Adds MammaPrint Gene Expression Assay to Breast Cancer Guidelines

February 14th 2023

The National Comprehensive Cancer Network breast cancer guidelines issued February 7, 2003, added the MammaPrint UltraLow Risk gene expression assay to its list of recommended assays for consideration of adjuvant systemic therapy.

Annamycin Achieves 80% ORR in Relapsed/Refractory Acute Myeloid Leukemia

February 13th 2023

Topline results from the phase 1 European MB-105 clinical trial showed that new safety results for annamycin, a next-generation anthracycline, are in keeping with previous findings for patients with relapsed/refractory acute myeloid leukemia.

NCCN Launches Health Equity Report Card to Address Racial Disparities in Cancer Care

February 10th 2023

The National Comprehensive Cancer Network has partnered with the American Cancer Society Cancer Action Network and the National Minority Quality Forum to launch the new Health Equity Report Card pilot program to address structural and interpersonal bigotry that results in disparities in cancer care and outcomes.

ONA-XR/Anastrozole Combo Delivers Promising Early Results in HR+ Metastatic Endometrial Cancer

February 8th 2023

Oral progesterone receptor antagonist onapristone extended release in combination with anastrozole induced a confirmed partial response in 2 patients with hormone receptor–positive metastatic endometrial cancer.

Immunotherapy Must Become More Precise and Personalized in Lung Cancer

February 7th 2023

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.

RaDaR Assay Predicts Patient Response to Immunotherapy in Stage III Bladder Cancer

February 6th 2023

The RaDaR assay successfully identified the patients with locoregionally advanced urothelial cancer most likely to benefit from treatment with ipilimumab and nivolumab in findings from the second cohort of the phase 1b/2a NABUCCO trial.

NCCN Adds Neratinib to New Metastatic Breast Cancer Guidelines

February 1st 2023

In recommendations released January 27, 2023, the National Comprehensive Cancer Network now advises physicians to consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of estrogen receptor status, with activating mutations in the HER2 gene as detected by next-generation sequencing of tumor tissue or circulating tumor DNA.

Neoadjuvant Chemo Reduces 2-Year Risk for Residual, Recurrent Disease by 28% in Colon Cancer

February 1st 2023

Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy did not increase perioperative morbidity in patients with radiologically staged T3-4, N0-2, M0 colon cancer, according to findings from the international phase 2/3 FOxTROT trial.

Researcher Highlights Need for Improved Understanding of Prostate Basal Cell Carcinoma

January 31st 2023

Basal cell carcinoma of the prostate is a rare variant of prostate cancer so uncommon that few physicians will ever treat the disease in their careers. Only 100 or so patients have been identified in the literature compared with more than 1 million diagnoses every year for adenocarcinoma.

FDA Grants Breakthrough Therapy Designation for Pimicotinib in TGCT

January 30th 2023

The FDA has granted a breakthrough therapy designation to pimicotinib for the treatment of patients with tenosynovial giant cell tumor who are not amenable for surgery.

Nanvuranlat Significantly Improves PFS in Pretreated, Advanced Biliary Tract Cancer

January 30th 2023

Nanvuranlat, a first-in-class LAT1 inhibitor, induced a statistically significant improvement in progression-free survival compared with placebo in patients with advanced, pretreated refractory biliary tract cancer.

NICE Recommends Axicabtagene Ciloleucel for Lymphoma

January 30th 2023

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of axicabtagene ciloleucel for adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma following at least 2 previous lines of systemic therapy.

FDA Awards Fast Track Designation to Tamibarotene for Increased-Risk MDS

January 26th 2023

The FDA has granted a fast track designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome.

PhD Candidate Discovers Increasing Risk for Liver Cancer Among US Residents of Mexican Descent

January 26th 2023

The risk for developing hepatocellular carcinoma appears to increase with subsequent generations for Americans of Mexican descent, according to findings from a study of US-born Hispanics/Latinos living in Los Angeles, California.

NCCN Recommends Sodium Thiosulfate to Reduce the Risk for Cisplatin-Induced Hearing Loss in Pediatric Patients

January 25th 2023

Fennec Pharmaceuticals announced an update to the National Comprehensive Cancer Network’s practice guidelines for Adolescent and Young Adult Oncology, calling for the use of sodium thiosulfate injection to reduce the risk for ototoxicity in pediatric patients receiving cisplatin.

Anti-drug Antibodies Do Not Affect Durvalumab Alone, With Tremelimumab in Unresectable HCC

January 20th 2023

The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.

Nivolumab Plus Ipilimumab or Chemo Maintains OS Benefit in ESCC in Long-Term Results

January 20th 2023

Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.

Signatera MRD Test Successfully Identifies Patients With CRC Most Likely to Benefit From Adjuvant Chemotherapy

January 19th 2023

The Signatera molecular residual disease test was able to detect patients with stage II to IV colorectal cancer who were at an increased risk for recurrence and predict which patients were most likely to benefit from adjuvant chemotherapy.

MRI-Guided Radiotherapy Significantly Reduces Genitourinary, Gastrointestinal AEs in Prostate Cancer

January 17th 2023

Patients who received MRI-guided stereotactic body radiotherapy for prostate cancer experienced fewer moderate acute physician-scored genitourinary and gastrointestinal adverse effects compared with those who received computed tomography–guided stereotactic body radiotherapy.